Who are bivalent rLP2086's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): batch 1 of Ad5-nCoV, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), TT, Combination BNT162b2 and BNT162b2 OMI, Influenza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bivalent-rlp2086.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

bivalent rLP2086 — Competitive Intelligence Brief

bivalent rLP2086 (bivalent rLP2086) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Infectious Disease.

phase 3 vaccine SARS-CoV-2 spike protein Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

bivalent rLP2086 (bivalent rLP2086) — Pfizer. bivalent rLP2086 is a vaccine that targets the SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
bivalent rLP2086 TARGET	bivalent rLP2086	Pfizer	phase 3	vaccine	SARS-CoV-2 spike protein
batch 1 of Ad5-nCoV	batch 1 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose	variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
TT	TT	CanSino Biologics Inc.	marketed	Viral vector vaccine	SARS-CoV-2 spike protein
Combination BNT162b2 and BNT162b2 OMI	combination-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Influenza	Influenza and COVID-19 Combination A	BioNTech	marketed	Non-Standardized Plant Allergenic Extract [EPC]	SARS-CoV-2 spike protein and influenza hemagglutinin protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bivalent rLP2086 — Competitive Intelligence Brief. https://druglandscape.com/ci/bivalent-rlp2086. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab